IM Cannabis Registers 2.8M Shares for Resale — 170% Dilution Overhang, CEO Among Sellers
IMCC is trading near its 52-week low of $1.55 (11% above the low) on light trading volume (0.1× avg).
Summary
IM Cannabis filed an F-3 to register 2.8 million shares for resale — about 170% of its current outstanding shares — including shares underlying a newly disclosed October 7 debt settlement and shares held by its CEO and a director.
Key Events · Financing and Capital Events · IMCC
-
2.8M Shares Registered for Resale
F-3 registers 2,799,276 shares for resale by selling shareholders, representing approximately 170% of the 1,647,494 shares currently outstanding.
-
October 7 Debt Settlement Disclosed
Newly disclosed October 7, 2026 debt settlement agreement issued US$490,770 in convertible notes with a US$0.40 floor price and 243,245 accompanying warrants.
-
CEO and Director Among Sellers
CEO Oren Shuster is registered to sell 577,008 shares and director Rafi Gabay 575,557 shares, each subject to a 4.99% beneficial ownership cap.
-
Minimal Proceeds Received
Company has received only US$630,000 in gross proceeds from the PIPE promissory notes, while the resale registration creates a massive overhang.
Analysis · IMCC · Life Sciences
This F-3 registers 2,799,276 shares for resale by selling shareholders, equal to roughly 170% of the 1,647,494 shares currently outstanding. The registration covers shares underlying three PIPE convertible notes (July, August, September 2026), a September 16 creditor settlement, and a newly disclosed October 7, 2026 debt settlement agreement issuing US$490,770 in convertible notes with a US$0.40 floor price. CEO Oren Shuster and director Rafi Gabay are among the selling shareholders, each registered to sell over 575,000 shares. The company has received only US$630,000 in gross proceeds from these financings, while the resale registration creates a massive overhang that could depress the stock price. The filing also confirms the company regained Nasdaq compliance on September 23, 2026 after a bid price deficiency, but the dilution risk remains severe.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $1.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $1.55 to $77.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.